3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

(2016) H. Bonnefoi et al.   ANNALS OF ONCOLOGY

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

(2016) N. Harbeck et al.   ANNALS OF ONCOLOGY

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

(2016) F. Roila et al.   ANNALS OF ONCOLOGY

Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys

(2016) Fatima Cardoso et al.   BREAST

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

(2016) L. M. Smyth et al.   BREAST CANCER RESEARCH AND TREATMENT

Abstract P1-15-06: Evaluation of miracle mouthwash (MMW) plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: Preliminary results of a randomized phase II study

(2016) VL Jones et al.   CANCER RESEARCH

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

(2016) Michael Untch et al.   LANCET ONCOLOGY

Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer

(2016) Willemijne A M E Schrijver et al.   MODERN PATHOLOGY

Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011

(2016) Alexandra Thomas et al.   JAMA Surgery

In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium

(2015) D. J. A. Lobbezoo et al.   ANNALS OF ONCOLOGY

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

(2015) N. I. Cherny et al.   ANNALS OF ONCOLOGY

Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial

(2015) Noémie Travier et al.   BMC Medicine

Screening, evaluation, and management of cancer-related fatigue: Ready for implementation to practice?

(2015) Ann M. Berger et al.   CA-A CANCER JOURNAL FOR CLINICIANS

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2015) Peter A. Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial

(2015) Rajendra Badwe et al.   LANCET ONCOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Clinical overview of metronomic chemotherapy in breast cancer

(2015) Elisabetta Munzone et al.   Nature Reviews Clinical Oncology

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer

(2015) Kokoro Kobayashi et al.   SURGERY TODAY

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

(2014) M. Piccart et al.   ANNALS OF ONCOLOGY

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

(2014) Debu Tripathy et al.   BMC CANCER

Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression-Free Survival on First-Line Therapy Predicts Overall Survival Impact

(2014) Daniel Rayson et al.   Breast Journal

Management of fatigue in patients with cancer – A practical overview

(2014) Rutger H.T. Koornstra et al.   CANCER TREATMENT REVIEWS

Breast cancer during follow-up and progression – A population based cohort on new cancers and changed biology

(2014) E. Karlsson et al.   EUROPEAN JOURNAL OF CANCER

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)

(2014) Fabrice André et al.   LANCET ONCOLOGY

Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status

(2013) Frédérique Penault-Llorca et al.   BREAST

Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2

(2013) Kathleen I. Pritchard et al.   Clinical Breast Cancer

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

(2013) Dino Amadori et al.   LANCET ONCOLOGY

1st International consensus guidelines for advanced breast cancer (ABC 1)

(2012) F. Cardoso et al.   BREAST

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

(2012) Rita S. Mehta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

453 Trends in survival in metastatic breast cancer

(2010) M. Sundquist et al.   EJC SUPPLEMENTS

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study

(2010) Michael Andersson et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY